OR WAIT null SECS
Recipharm has signed a memorandum of understanding (MOU) with His Majesty the King of Morocco, the Moroccan government, and a consortium of leading banks from the country, for fill/finish capacity in the country.
Contract development and manufacturing organization (CDMO), Recipharm, has signed a memorandum of understanding (MOU) with His Majesty the King of Morocco, the Moroccan government, and a consortium of leading banks from the country, for fill/finish capacity in the country.
The agreement will see investment worth approximately $500 million from the Moroccan government and consortium of banks over the next five years that will be used to establish capacity and capability for the manufacture of vaccines and biotherapeutics in Morocco. The new facility, which will be located on a 42-hectare greenfield site, is primarily aimed at providing the African continent with supply of vaccines and biotherapeutics and is expected to be operational by 2023. The facility will mirror Recipharm’s fill/finish line in Monts, France but on a larger scale.
“It’s an honour to act as the CDMO of choice on this project. Together with the other parties involved, we will be able to work to offer Africa a concrete opportunity to gradually gain health independence from western countries and ultimately help to ensure it is less vulnerable in times of crisis,” said Marc Funk, CEO of Recipharm, in a July 6, 2021 press release. “Our expertise and previous experience of fill finish manufacturing means we’re ideally placed to ensure successful tech transfer and high-quality operations.”